Co-therapy with vector and nicotinic agonist
Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; heb |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | NAU Jeffrey Alan CARLSON Eric C |
| description | Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a drug such as an nAChRα7 agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, 5-{(E)-2-[(3R)-pyrrolidin-3-yl]vinyl}pyrimidine, or (R,E)-5-(2-pyrrolidine-3-yl)vinyl)pyrimidine). The primary therapeutic agents provided include recombinant adeno-associated virus (AAV) vectors expressing a therapeutic gene product (e.g., a biologic drug). Related compositions methods of use are also provided. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL308372A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL308372A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL308372A3</originalsourceid><addsrcrecordid>eNrjZNBxztctyUgtSiyoVCjPLMlQKEtNLskvUkjMS1HIy0zOL8kEkgqJ6fl5mcUlPAysaYk5xam8UJqbQc7NNcTZQze1ID8-tbggMTk1L7Uk3tPH2MDC2NzI0ZigAgCgmiiW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Co-therapy with vector and nicotinic agonist</title><source>esp@cenet</source><creator>NAU Jeffrey Alan ; CARLSON Eric C</creator><creatorcontrib>NAU Jeffrey Alan ; CARLSON Eric C</creatorcontrib><description>Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a drug such as an nAChRα7 agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, 5-{(E)-2-[(3R)-pyrrolidin-3-yl]vinyl}pyrimidine, or (R,E)-5-(2-pyrrolidine-3-yl)vinyl)pyrimidine). The primary therapeutic agents provided include recombinant adeno-associated virus (AAV) vectors expressing a therapeutic gene product (e.g., a biologic drug). Related compositions methods of use are also provided.</description><language>eng ; heb</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240101&DB=EPODOC&CC=IL&NR=308372A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240101&DB=EPODOC&CC=IL&NR=308372A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAU Jeffrey Alan</creatorcontrib><creatorcontrib>CARLSON Eric C</creatorcontrib><title>Co-therapy with vector and nicotinic agonist</title><description>Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a drug such as an nAChRα7 agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, 5-{(E)-2-[(3R)-pyrrolidin-3-yl]vinyl}pyrimidine, or (R,E)-5-(2-pyrrolidine-3-yl)vinyl)pyrimidine). The primary therapeutic agents provided include recombinant adeno-associated virus (AAV) vectors expressing a therapeutic gene product (e.g., a biologic drug). Related compositions methods of use are also provided.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNBxztctyUgtSiyoVCjPLMlQKEtNLskvUkjMS1HIy0zOL8kEkgqJ6fl5mcUlPAysaYk5xam8UJqbQc7NNcTZQze1ID8-tbggMTk1L7Uk3tPH2MDC2NzI0ZigAgCgmiiW</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>NAU Jeffrey Alan</creator><creator>CARLSON Eric C</creator><scope>EVB</scope></search><sort><creationdate>20240101</creationdate><title>Co-therapy with vector and nicotinic agonist</title><author>NAU Jeffrey Alan ; CARLSON Eric C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL308372A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>NAU Jeffrey Alan</creatorcontrib><creatorcontrib>CARLSON Eric C</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAU Jeffrey Alan</au><au>CARLSON Eric C</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Co-therapy with vector and nicotinic agonist</title><date>2024-01-01</date><risdate>2024</risdate><abstract>Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a drug such as an nAChRα7 agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, 5-{(E)-2-[(3R)-pyrrolidin-3-yl]vinyl}pyrimidine, or (R,E)-5-(2-pyrrolidine-3-yl)vinyl)pyrimidine). The primary therapeutic agents provided include recombinant adeno-associated virus (AAV) vectors expressing a therapeutic gene product (e.g., a biologic drug). Related compositions methods of use are also provided.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; heb |
| recordid | cdi_epo_espacenet_IL308372A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | Co-therapy with vector and nicotinic agonist |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A25%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAU%20Jeffrey%20Alan&rft.date=2024-01-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL308372A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |